Search

Your search keyword '"S. Guazzieri"' showing total 3 results
Start Over Author "S. Guazzieri" Search Limiters Full Text
3 results on '"S. Guazzieri"'

1. Clinical validation of the iXip index in avoiding unnecessary prostate biopsy: Results from a prospective multicenter study involving 426 patients

Author

Gianluca Giannarini, Danilo Zani, Lucio Laurini, A. Garbeglio, Filiberto Zattoni, Mario Plebani, Andrea Gallotta, Giorgio Fassina, and S. Guazzieri

Subjects
Oncology, PCA3, Cancer Research, medicine.medical_specialty, Prostate biopsy, 030232 urology & nephrology, prostatic neoplasm, PSA, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, Prostate, Internal medicine, Biopsy, Medicine, prostate biopsy, Prostate Health Index, Prostate CAncer Gene 3, medicine.diagnostic_test, business.industry, PSA-IgM, Cancer, biomarker, diagnostic accuracy, iXip, medicine.disease, medicine.anatomical_structure, Multicenter study, 030220 oncology & carcinogenesis, Biomarker (medicine), business
Abstract

Purpose To assess the diagnostic accuracy of iXip, a novel biomarker for prostate cancer detection at initial biopsy based on an algorithm including patient age, prostate volume, PSA and PSA-IgM levels,. Materials and methods This was a prospective multicenter study involving 426 consecutive men undergoing initial prostate biopsy with at least 12 cores in a real-life clinical setting. Diagnostic accuracy of iXip for prostate cancer detection was calculated with AUC and compared to that of prostate volume, PSA and PSA-IgM levels. The correlation of iXip with tumor aggressiveness, defined as any cancer with Gleason score ≥7, was evaluated by Spearman ρ coefficient analysis. Results Prostate cancer was diagnosed in 193/426 patients (45%), of which 65 (35%) had Gleason score ≥7. iXip values were significantly higher in patients with cancer than in those without cancer (median value 55% vs. 39%, p Conclusions Our prospective multicenter study suggests that the novel biomarker iXip may be used with a 20% cut-off value in order to reduce the proportion of prostate biopsies by approximately 5%, without missing a single case of cancer. Moreover, higher iXip values are significantly correlated with tumor aggressiveness.

Published
2017

2. 263 High grade pin in prostate biopsies and cancer detection on re-biopsy. The cancer found is significant on the pathological point of view

Author

G. Anselmo, Giovanni Muzzonigro, S. Guazzieri, Giovanni Liguori, Andrea Fandella, Alessandro Bertaccini, G. D'Incà, G. L. Drago-Ferrante, Andrea B. Galosi, Giuseppe Martorana, Patrizio Rigatti, Vincenzo Scattoni, Carlo Trombetta, Fandella, A., Scattoni, V., Rigatti, P., Bertaccini, A., Martorana, G., Drago-Ferrante, G., Anselmo, G., Galosi, A., Muzzonigro, G., D'Incà, G., Guazzieri, S., Liguori, G., and Trombetta, C.

Subjects
Pathology, medicine.medical_specialty, prostate, medicine.diagnostic_test, business.industry, diagnosis, Urology, Cancer, Cancer detection, medicine.disease, High grade pin, prostate, biopsy, diagnosis, High-Grade PIN, medicine.anatomical_structure, Prostate, Biopsy, Re biopsy, medicine, High grade pin, biopsy, Radiology, business, Pathological
Published
2004

3. Effects of complete androgen blockade for 12 and 24 weeks on the pathological stage and resection margin status of prostate cancer.

Author

Selli C, Montironi R, Bono A, Pagano F, Zattoni F, Manganelli A, Selvaggi FP, Comeri G, Fiaccavento G, Guazzieri S, Lembo A, Cosciani-Cunico S, Potenzoni D, Muto G, Mazzucchelli R, and Santinelli A

Subjects
Aged, Anilides therapeutic use, Biopsy, Chemotherapy, Adjuvant, Drug Administration Schedule, Goserelin therapeutic use, Humans, Male, Middle Aged, Neoadjuvant Therapy, Neoplasm Staging, Nitriles, Prospective Studies, Prostatectomy, Prostatic Neoplasms pathology, Prostatic Neoplasms surgery, Tosyl Compounds, Androgen Antagonists therapeutic use, Antineoplastic Agents, Hormonal therapeutic use, Prostatic Neoplasms drug therapy
Abstract

Aims: To compare the pathological stage and surgical margin status in patients undergoing either immediate radical prostatectomy or 12 and 24 weeks of neoadjuvant hormonal treatment (NHT) in a prospective, randomised study., Methods: Whole mount sections of 393 radical prostatectomy specimens were evaluated: 128 patients had immediate surgery, 143 were treated for 12 weeks and 122 for 24 weeks with complete androgen blockade., Results: Histopathology revealed organ confined tumours in 40.4% of patients with clinical stage B disease in the immediate surgery group, whereas 12 and 24 weeks of NHT increased the number of organ confined tumours to 54.6% and 64.8%, respectively. Among patients with clinical stage C tumours, pathological staging found organ confined disease in 10.4%, 31.4%, and 61.2% in the immediate surgery, 12 weeks of NHT, and 24 weeks of NHT groups, respectively. Preoperative NHT caused a significant decrease in positive margins both in patients with clinical stage B and C disease. The extent of margin involvement was not influenced by preoperative treatment., Conclusions: Neoadjuvant androgenic suppression is effective in reducing both the pathological stage and the positive margin rate in patients with stage B and C prostatic cancer undergoing radical surgery. Some beneficial effects are evident in those patients treated for 24 weeks, and it is reasonable to assume that the optimal duration of NHT is longer than three months.

Published
2002
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results